Trimetazidine is a drug for angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism, also known as fatty acid oxidation inhibitor.
· Cas No: 13171-25-0
· Chemical Composition: C14H22N2O3.2HCl
· Molecular wt.: 339.26
· Description: A white Crystalline Powder, Slightly hygroscopic.
· Solubility: Soluble in water, sparingly soluble in ethanol & practically insoluble in ether
· Heavy Metals: Limit: Max. 20 PPM
· Arsenic: Limit :Max.2PPM
· Ph of Solution ( 1 in 20): Limit : 2.3 to 3.3
· Clarity And Colour of the Solution: Clear and Colourless Solution
· Melting Point: Limit : 225o to 227o
· Residue on Ignition: Limit : Max. 0.2 %
· Loss on drying: Limit : Max.:2%
· Assay: Limit: Min. 98%
Packaging details:
Packaging details: |
25kg/drum with double plastic bags inside; packed in a cardboard drum or fiber HDPE drum. |
Storage: |
Stored in a clean, cool, dry area; keep away from moisture and strong, direct light/heat |
Shelf Life: |
5 years if sealed and store away from direct sun light. |